Role of the B1 bradykinin receptor and gC1qR/p33 in angioedema

Patients affected by angioedema (AE) are subject to asymmetric, nonerythematous, nonpruritic, localized, transient, episodic swelling of deeper layers or submucosal tissues of the skin, oropharyngolaryngeal tissue, and/or gastrointestinal wall. The nonapeptide bradykinin (BK) may be largely responsi...

Full description

Saved in:
Bibliographic Details
Published inImmunology and allergy clinics of North America Vol. 33; no. 4; p. 535
Main Authors Bossi, Fleur, Tedesco, Francesco
Format Journal Article
LanguageEnglish
Published United States 01.11.2013
Subjects
Angioedema - diagnosis
Angioedema - metabolism
Bradykinin - secretion
Carrier Proteins - metabolism
Endothelial Cells - metabolism
Humans
Mitochondrial Proteins - metabolism
Receptor, Bradykinin B1 - metabolism
gC1qR/p33
Vascular leakage
Angioedema
BK 1 receptor
BK 2 receptor
Online AccessGet more information

Cover

More Information
Summary:Patients affected by angioedema (AE) are subject to asymmetric, nonerythematous, nonpruritic, localized, transient, episodic swelling of deeper layers or submucosal tissues of the skin, oropharyngolaryngeal tissue, and/or gastrointestinal wall. The nonapeptide bradykinin (BK) may be largely responsible for the vascular permeability seen in most AE. During AE attacks, activation of the serine proteases leads to the release of BK. Enzymes expressed on the endothelial cell membrane can metabolize BK, producing the agonist of the B1R, which can then be upregulated by proinflammatory stimuli, suggesting that the blockade of B1R and B2R, or gC1q/p33, may provide novel therapeutic targets.
ISSN:1557-8607
DOI:10.1016/j.iac.2013.07.008